Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT07348172
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Drug Liking

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Amisulpride — DRUG
    Medication administered as a single intravenous dose.
  • Placebo — DRUG
    Matching Placebo given by single intravenous (IV) administration.

Study Details

The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.

Key Dates

Start date
Mar 1, 2026
Status verified
Jan 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Drug
    Participants receive study drug prior to fentanyl administration before their procedure.
  • Placebo Comparator: Placebo
    Participants receive placebo prior to fentanyl administration before their procedure.

Primary Outcome Measure

Change in Drug Liking Rating [ Time Frame: One minute before and 1, 3, and 5 minutes after fentanyl administration ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford HospitalPalo AltoCalifornia94304
Patrick Principal Investigator
[email protected]
6179706739

Find similar trials in Palo Alto, CA

By research site
Stanford Hospital· Palo Alto, CA

Related Studies